oradrenalin vs terlipressin in patients with hepatorenal syndrome - ND
- Conditions
- Hepatorenal syndromeMedDRA version: 8.1Level: LLTClassification code 10019846Term: Hepatorenal syndrome
- Registration Number
- EUCTR2006-005090-21-IT
- Lead Sponsor
- AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
-All consecutive patients with hepaatorenal syndrome type 1 and 2 -Age between 18 and 75 years 3-Informed written consent 4-Absence of exclusion criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
-Age 75 years -Hepatocellular caarcinoma -Active bacterial infection -Gaastrointestinaal bleeding within the previous week -Hearth and respiratory failure - Distal arteriopathy - History of CAD - Arterial hypertension
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Effects of noradrenalin vs terlipressin on systemic haemodynamics and renal function in patients with hepaatorenal syndrome. Tolerability. Cost-effectivess study.;Secondary Objective: 1. Hepatic function. 2. Vasoactive systems plasma renin activity, plasma aldosterone;Primary end point(s): renal function
- Secondary Outcome Measures
Name Time Method